These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 21707531)
21. Erythropoietin and erythropoietin receptor expression after experimental spinal cord injury encourages therapy by exogenous erythropoietin. Grasso G; Sfacteria A; Passalacqua M; Morabito A; Buemi M; Macrì B; Brines ML; Tomasello F Neurosurgery; 2005 Apr; 56(4):821-7; discussion 821-7. PubMed ID: 15792521 [TBL] [Abstract][Full Text] [Related]
22. A new paradigm for local and sustained release of therapeutic molecules to the injured spinal cord for neuroprotection and tissue repair. Kang CE; Poon PC; Tator CH; Shoichet MS Tissue Eng Part A; 2009 Mar; 15(3):595-604. PubMed ID: 18991489 [TBL] [Abstract][Full Text] [Related]
23. Delayed treatment of spinal cord injury with erythropoietin or darbepoetin--a lack of neuroprotective efficacy in a contusion model of cord injury. Mann C; Lee JH; Liu J; Stammers AM; Sohn HM; Tetzlaff W; Kwon BK Exp Neurol; 2008 May; 211(1):34-40. PubMed ID: 18313052 [TBL] [Abstract][Full Text] [Related]
24. Erythropoietin preconditioning improves clinical and histologic outcome in an acute spinal cord ischemia and reperfusion rabbit model. Simon FH; Erhart P; Vcelar B; Scheuerle A; Schelzig H; Oberhuber A J Vasc Surg; 2016 Dec; 64(6):1797-1804. PubMed ID: 26610640 [TBL] [Abstract][Full Text] [Related]
25. High-dose erythropoietin alters platelet reactivity and bleeding time in rodents in contrast to the neuroprotective variant carbamyl-erythropoietin (CEPO). Kirkeby A; Torup L; Bochsen L; Kjalke M; Abel K; Theilgaard-Monch K; Johansson PI; Bjørn SE; Gerwien J; Leist M Thromb Haemost; 2008 Apr; 99(4):720-8. PubMed ID: 18392330 [TBL] [Abstract][Full Text] [Related]
26. AMP-activated protein kinase-dependent induction of autophagy by erythropoietin protects against spinal cord injury in rats. Wang P; Xie ZD; Xie CN; Lin CW; Wang JL; Xuan LN; Zhang CW; Wang Y; Huang ZH; Teng HL CNS Neurosci Ther; 2018 Dec; 24(12):1185-1195. PubMed ID: 29656591 [TBL] [Abstract][Full Text] [Related]
27. Nonhematopoietic erythropoietin derivatives prevent motoneuron degeneration in vitro and in vivo. Mennini T; De Paola M; Bigini P; Mastrotto C; Fumagalli E; Barbera S; Mengozzi M; Viviani B; Corsini E; Marinovich M; Torup L; Van Beek J; Leist M; Brines M; Cerami A; Ghezzi P Mol Med; 2006; 12(7-8):153-60. PubMed ID: 17088947 [TBL] [Abstract][Full Text] [Related]
28. Delayed administration of recombinant human erythropoietin reduces apoptosis and inflammation and promotes myelin repair and functional recovery following spinal cord compressive injury in rats. Yang L; Yan X; Xu Z; Tan W; Chen Z; Wu B Restor Neurol Neurosci; 2015 Oct; 34(4):647-63. PubMed ID: 26444376 [TBL] [Abstract][Full Text] [Related]
29. Erythropoietin effect on sensorimotor recovery after contusive spinal cord injury: an electrophysiological study in rats. Cerri G; Montagna M; Madaschi L; Merli D; Borroni P; Baldissera F; Gorio A Neuroscience; 2012 Sep; 219():290-301. PubMed ID: 22659566 [TBL] [Abstract][Full Text] [Related]
30. Erythropoietin plus methylprednisolone or methylprednisolone in the treatment of acute spinal cord injury: a preliminary report. Alibai E; Zand F; Rahimi A; Rezaianzadeh A Acta Med Iran; 2014; 52(4):275-9. PubMed ID: 24901857 [TBL] [Abstract][Full Text] [Related]
31. A re-assessment of erythropoietin as a neuroprotective agent following rat spinal cord compression or contusion injury. Pinzon A; Marcillo A; Pabon D; Bramlett HM; Bunge MB; Dietrich WD Exp Neurol; 2008 Sep; 213(1):129-36. PubMed ID: 18625498 [TBL] [Abstract][Full Text] [Related]
32. Post-ischemic treatment with erythropoietin or carbamylated erythropoietin reduces infarction and improves neurological outcome in a rat model of focal cerebral ischemia. Wang Y; Zhang ZG; Rhodes K; Renzi M; Zhang RL; Kapke A; Lu M; Pool C; Heavner G; Chopp M Br J Pharmacol; 2007 Aug; 151(8):1377-84. PubMed ID: 17603558 [TBL] [Abstract][Full Text] [Related]
33. Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma. Gorio A; Gokmen N; Erbayraktar S; Yilmaz O; Madaschi L; Cichetti C; Di Giulio AM; Vardar E; Cerami A; Brines M Proc Natl Acad Sci U S A; 2002 Jul; 99(14):9450-5. PubMed ID: 12082184 [TBL] [Abstract][Full Text] [Related]
34. Asialoerythropoietin attenuates neuronal cell death in the hippocampal CA1 region after transient forebrain ischemia in a gerbil model. Yamashita T; Nonoguchi N; Ikemoto T; Miyatake S; Kuroiwa T Neurol Res; 2010 Nov; 32(9):957-62. PubMed ID: 20444326 [TBL] [Abstract][Full Text] [Related]
35. Erythropoietin 2nd cerebral protection after acute injuries: a double-edged sword? Velly L; Pellegrini L; Guillet B; Bruder N; Pisano P Pharmacol Ther; 2010 Dec; 128(3):445-59. PubMed ID: 20732352 [TBL] [Abstract][Full Text] [Related]
36. Methylprednisolone neutralizes the beneficial effects of erythropoietin in experimental spinal cord injury. Gorio A; Madaschi L; Di Stefano B; Carelli S; Di Giulio AM; De Biasi S; Coleman T; Cerami A; Brines M Proc Natl Acad Sci U S A; 2005 Nov; 102(45):16379-84. PubMed ID: 16260722 [TBL] [Abstract][Full Text] [Related]
37. Evaluation of the effects of erythropoietin and interleukin-6 in rats submitted to acute spinal cord injury. Barros AGC; Cristante AF; Santos GBD; Natalino RJM; Ferreira RJR; Barros-Filho TEP Clinics (Sao Paulo); 2019; 74():e674. PubMed ID: 31433044 [TBL] [Abstract][Full Text] [Related]
38. Facile fabrication of an erythropoietin-alginate/chitosan hydrogel and evaluation of its local therapeutic effects on spinal cord injury in rats. Gholami M; Gilanpour H; Sadeghinezhad J; Asghari A Daru; 2021 Dec; 29(2):255-265. PubMed ID: 34491566 [TBL] [Abstract][Full Text] [Related]